Table 4 Summary of TEAEs and TESAEs in the four groups
Arm A | Arm B | Arm C | Arm D | |
|---|---|---|---|---|
(N=59) | (N=62) | (N=58) | (N=59) | |
N(%) | N(%) | N(%) | N(%) | |
TEAEs: | ||||
Subject with at least one TEAE | 57 (96.6) | 58 (93.5) | 53 (91.4) | 56 (94.9) |
Subject discontinued the study due to TEAE | 4 (6.8) | 4 (6.5) | 6 (10.3) | 8 (13.6) |
Subjects with at least one chemotherapy-related TEAE | 56 (94.9) | 57 (91.9) | 50 (86.2) | 55 (93.2) |
Subjects without TEAE | 2 (3.4) | 4 (6.5) | 5 (8.6) | 3 (5.1) |
TESAEs: | ||||
Subject with at least one TESAE | 9 (15.3) | 10 (16.0) | 7 (12.1) | 11 (18.6) |
Subjects with at least one chemotherapy-related TESAE | 5 (8.5) | 4 (6.5) | 3 (5.2) | 5 (8.5) |